Revenue Breakdown
Composition ()
No data
Revenue Streams
Rockwell Medical Inc (RMTI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Concentrate Products, accounting for 98.3% of total sales, equivalent to $18.59M. Another important revenue stream is Drug Products. Understanding this composition is critical for investors evaluating how RMTI navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Rockwell Medical Inc maintains a gross margin of 17.40%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.81%, while the net margin is -11.01%. These profitability ratios, combined with a Return on Equity (ROE) of -17.02%, provide a clear picture of how effectively RMTI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RMTI competes directly with industry leaders such as EKSO and NMTC. With a market capitalization of $35.48M, it holds a significant position in the sector. When comparing efficiency, RMTI's gross margin of 17.40% stands against EKSO's 53.22% and NMTC's 54.20%. Such benchmarking helps identify whether Rockwell Medical Inc is trading at a premium or discount relative to its financial performance.
